Brokerages expect that Five Prime Therapeutics Inc (NASDAQ:FPRX) will report $8.00 million in sales for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Five Prime Therapeutics’ earnings. The lowest sales estimate is $4.10 million and the highest is $13.42 million. Five Prime Therapeutics reported sales of $13.22 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 39.5%. The firm is expected to announce its next quarterly earnings report on Tuesday, February 26th.

On average, analysts expect that Five Prime Therapeutics will report full year sales of $52.48 million for the current year, with estimates ranging from $49.94 million to $53.84 million. For the next fiscal year, analysts expect that the firm will post sales of $28.86 million, with estimates ranging from $7.30 million to $60.00 million. Zacks’ sales averages are an average based on a survey of analysts that follow Five Prime Therapeutics.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($1.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.15) by ($0.22). Five Prime Therapeutics had a negative net margin of 221.67% and a negative return on equity of 41.52%. The business had revenue of $5.77 million during the quarter, compared to analysts’ expectations of $7.45 million.

A number of research firms recently weighed in on FPRX. Wells Fargo & Co decreased their price target on Five Prime Therapeutics from $58.00 to $35.00 and set an “outperform” rating on the stock in a research note on Thursday, August 9th. Wedbush lifted their price target on Five Prime Therapeutics from $17.00 to $19.00 and gave the company a “hold” rating in a research note on Friday, August 10th. Leerink Swann began coverage on Five Prime Therapeutics in a research note on Thursday, September 13th. They issued an “outperform” rating and a $24.00 price target on the stock. BidaskClub upgraded Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, October 19th. Finally, Citigroup decreased their price target on Five Prime Therapeutics from $60.00 to $44.00 and set a “buy” rating on the stock in a research note on Monday, August 20th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Five Prime Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $29.67.

Five Prime Therapeutics stock opened at $12.90 on Friday. Five Prime Therapeutics has a 1-year low of $10.35 and a 1-year high of $24.82. The company has a market capitalization of $451.12 million, a P/E ratio of -2.40 and a beta of 3.34.

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in Five Prime Therapeutics by 3.0% during the third quarter. Vanguard Group Inc. now owns 2,251,778 shares of the biotechnology company’s stock worth $31,344,000 after purchasing an additional 66,485 shares during the last quarter. MetLife Investment Advisors LLC raised its holdings in Five Prime Therapeutics by 54.6% during the third quarter. MetLife Investment Advisors LLC now owns 30,852 shares of the biotechnology company’s stock worth $429,000 after purchasing an additional 10,895 shares during the last quarter. Platinum Investment Management Ltd. raised its holdings in Five Prime Therapeutics by 29.1% during the third quarter. Platinum Investment Management Ltd. now owns 121,576 shares of the biotechnology company’s stock worth $1,692,000 after purchasing an additional 27,376 shares during the last quarter. BlueMountain Capital Management LLC raised its holdings in Five Prime Therapeutics by 398.9% during the third quarter. BlueMountain Capital Management LLC now owns 14,766 shares of the biotechnology company’s stock worth $206,000 after purchasing an additional 11,806 shares during the last quarter. Finally, Wexford Capital LP acquired a new position in Five Prime Therapeutics during the third quarter worth $1,569,000. 85.99% of the stock is owned by hedge funds and other institutional investors.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

Read More: What are the Benefits of Index Funds?

Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.